TUCSON, Ariz., Oct. 28, 2015 /PRNewswire/ -- HSRx Group, an Arizona-based biopharmaceutical company that is a leader in the development of next generation combination drugs for chronic and infectious diseases, has completed the influenza prevention segment of a prevention and treatment study begun in November 2014. The phase II-sized study is designed to demonstrate the clinical significance of the HSRx 351 combination drug compared to the leading oral treatment, Tamiflu® (oseltamivir). A proprietary HSRx food-based compound, HSRx 351 is combined with generic oseltamivir to create a new oral flu treatment with a potential long patent life that deploys multiple flu virus-fighting mechanisms to safely achieve a higher level of effectiveness.
“HSRx 351 exemplifies the safe and powerful next generation combination drugs that HSRx Group is developing,” said HSRx Managing Director Thomas Sullivan, Jr. “Seasonal flu epidemics and the flu pandemic predicted by public health experts require a more effective oral prevention and treatment drug with a long shelf life, to enable stockpiling. HSRx 351 is the solution.”
“Oseltamivir works by attaching to a protein that coats influenza viruses to interrupt the reproduction of the virus,” said Joshua Costin, Ph.D., a Tulane-trained virologist. “HSRx 351 uniquely binds to a second influenza virus protein coating the virus to prevent it from attaching to the human cell. This combination of abilities effectively and immediately shuts down the viral infection cascade. The HSRx combination drug provides us with a powerful influenza treatment and prevention breakthrough that is needed to curb the sudden breakouts of this relentless disease.”
About HSRx Group
HSRx Group is a biopharmaceutical company developing next generation combination OTC and breakthrough drugs for the prevention and treatment of a broad group of chronic and infectious disease conditions. The HSRx technology integrates disease-fighting food nutrients with leading generic drugs to create multi-mechanism pharmaceutical products with long patent lives. Information is available at HSRxGroup.com.
Contact: | Matt Russell |
Russell Public Communications | |
(520) 232-9840 | |
Logo - http://photos.prnewswire.com/prnh/20151027/281138LOGO
Video - http://youtu.be/91SQHHg5q44
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hsrx-group-completes-influenza-prevention-phase-in-study-of-novel-combination-drug-for-flu-prevention--treatment-300167856.html
SOURCE HSRx Group
Help employers find you! Check out all the jobs and post your resume.
